Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ZSF1 studies, which are common models to study key features of heart failure ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its ...

For patients with HFPEF and other underlying comorbidities, such as diabetes or coronary artery disease, treatment with an ACE inhibitor is nonetheless beneficial. The theoretical benefits of ACE ...

Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...

"We have four pillars of guideline-directed medical therapy in HFrEF, but only SGLT2 inhibitors as a treatment option for HFmrEF/HFpEF," he said. "Given that finerenone was beneficial in patients ...

Sci & Tech and currently in Phase III for Systolic Heart Failure. According to GlobalData, Phase III drugs for Systolic Heart Failure have a 63% phase transition success rate (PTSR) indication ...

THRV-1268 is under clinical development by Thryv Therapeutics and currently in Phase I for Atrial Fibrillation.

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.